寡转移前列腺癌手术治疗的相关问题

许传亮; 常易凡; 孙颖浩

doi:10.13201/j.issn.1001-1420.2017.09.001

寡转移前列腺癌手术治疗的相关问题

- 海军军医大学附属长海医院泌尿外科(上海, 200433)

详细信息

通讯作者: 孙颖浩,E-mail:sunyhsmmu@126.com

中图分类号: R737.25

收稿日期: 2017-08-15

Radical prostatectomy for oligometastatic prostate cancer: perspectives and limitations

- Departmentof Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China

More Information

Corresponding author: SUN Yinghao, E-mail: sunyhsmmu@126.com

Received Date: 15 August 2017

摘要

摘要: 对于寡转移前列腺癌，越来越多的研究提出行原发灶手术切除可获得相比单纯内分泌治疗更优的生存期和更高的生活质量。近年来，国际指南的更新反映了前列腺癌手术治疗的指征正逐渐放宽，这为寡转移前列腺癌的外科治疗提供了额外的治疗思路。然而，现有研究证据仍限于临床研究阶段，寡转移前列腺癌的影像学诊断尚存在较大发展空间，寡转移前列腺癌的概念与定义尚未得到统一，手术治疗的适应证与治疗时机亦不明确，期待后续前瞻性随机对照研究提供更高等级的临床证据。
- 寡转移前列腺癌 /
- 前列腺癌根治术 /
- 影像学诊断
Abstract: As for oligometastatic prostate cancer, agrowing number of studies have indicated that performing radical prostatectomy of the primary tumor may yield better survival and higher quality of life compared with androgen deprivation therapy alone.Update of international guidelines in recent years have reflected a broadened spectrum of indications of radical prostatectomy, providing additional treatment strategies for oligometastatic prostate cancer.However, current evidence is limited to clinical investigations, and novel imaging technology of oligometastatic prostate cancer is still on the rise.Conceptions and definition of oligometastatic prostate cancer itself is still inconsistent, and the indications and timing of performing radical prostatectomy in such case scenario remain unclear.Further prospective randomized controlled clinical studies are required for higher level clinical evidence for future applications.
- oligometastatic prostate cancer /
- radical prostatectomy /
- imaging

HTML全文

参考文献(29)

[1]	Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136 (5):E359-386.
[2]	Hayat M J, Howlader N, Reichman M E, et al.Cancer statistics, trends, and multiple primary cancer analysis from the Surveillance, Epidemiology, and End Results (SEER) program[J].Oncologist, 2007, 12 (1):20-37.
[3]	Taylor L G, Canfield S E, Du X L.Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer[J].Cancer, 2009, 115 (11):2388-2399.
[4]	Tzelepi V, Efstathiou E, Wen S, et al.Persistent, biologically meaningful prostate cancer after 1year of androgen ablation and docetaxel treatment[J].J Clin Oncol, 2011, 29 (18):2574-2581.
[5]	Gomez D R, Blumenschein G R, Lee J J, et al.Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-smallcell lung cancer without progression after first-line systemic therapy:a multicentre, randomised, controlled, phase 2study[J].Lancet Oncol, 2016, 17 (12):1672-1682.
[6]	Glehen O, Mohamed F, Gilly F N.Peritoneal carcinomatosis from digestive tract cancer:new management by cytoreductive surgery and intraperitoneal chemohyperthermia[J].Lancet Oncol, 2004, 5 (4):219-228.
[7]	Bristow R E, Tomacruz R S, Armstrong D K, et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis[J].J Clin Oncol, 2002, 20 (5):1248-1259.
[8]	Group E B C T C.Polychemotherapy for early breast cancer:an overview of the randomised trials[J].Lancet, 1998, 352 (9132):930-942.
[9]	Flanigan R C, Salmon S E, Blumenstein B A, et al.Nephrectomy followed by interferon alfa-2bcompared with interferon alfa-2balone for metastatic renal-cell cancer[J].N Engl J Med, 2001, 345 (23):1655-1659.
[10]	Wiegand L R, Hernandez M, Pisters L L, et al.Surgical management of lymph-node-positive prostate cancer:improves symptomatic control[J].BJU Int, 2011, 107 (8):1238-1242.
[11]	Moschini M, Briganti A, Murphy C R, et al.Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy[J].Eur Urol, 2016, 69 (2):193-196.
[12]	Hellman S, Weichselbaum R R.Oligometastases[J].JClin Oncol, 1995, 13 (1):8-10.
[13]	Tran P T, Antonarakis E S.Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies:Reality Versus Illusion[J].J Oncol Pract, 2017, 13 (1):21-24.
[14]	Koizumi M, Yoshimoto M, Kasumi F, et al.Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients[J].Ann Oncol, 2003, 14 (8):1234-1240.
[15]	Cifuentes F F, Valenzuela R H, Contreras H R, et al.Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer[J].Oncol Rep, 2015, 34 (6):2837-2844.
[16]	Metcalfe M J, Smaldone M C, Lin D W, et al.Role of radical prostatectomy in metastatic prostate cancer:Areview[J].Urol Oncol, 2017, 35 (4):125-134.
[17]	Singh D, Yi W S, Brasacchio R A, et al.Is there a favorable subset of patients with prostate cancer who develop oligometastases?[J].Int J Radiat Oncol Biol Phys, 2004, 58 (1):3-10.
[18]	Culp S H, Schellhammer P F, Williams M B.Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor?A SEER-based study[J].Eur Urol, 2014, 65 (6):1058-1066.
[19]	Heidenreich A, Pfister D, Porres D.Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases:results of a feasibility and case-control study[J].J Urol, 2015, 193 (3):832-838.
[20]	Gandaglia G, Fossati N, Stabile A, et al.Radical Prostatectomy in Men with Oligometastatic Prostate Cancer:Results of a Single-institution Series with Long-term Follow-up[J].Eur Urol, 2017, 72 (2):289-292.
[21]	Sooriakumaran P, Karnes J, Stief C, et al.A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation[J].Eur Urol, 2016, 69 (5):788-794.
[22]	Antwi S, Everson T M.Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis:A population-based, propensity score analysis[J].Cancer Epidemiol, 2014, 38 (4):435-441.
[23]	Gratzke C, Engel J, Stief C G.Role of radical prostatectomy in metastatic prostate cancer:data from the Munich Cancer Registry[J].Eur Urol, 2014, 66 (3):602-603.
[24]	Satkunasivam R, Kim A E, Desai M, et al.Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer:A SEER-Medicare Analysis[J].J Urol, 2015, 194 (2):378-385.
[25]	Lindenberg M L, Turkbey B, Mena E, et al.Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer:A Review[J].JAMA Oncol, 2017.
[26]	Tosoian J J, Gorin M A, Ross A E, et al.Oligometastatic prostate cancer:definitions, clinical outcomes, and treatment considerations[J].Nat Rev Urol, 2017, 14 (1):15-25.
[27]	van Leeuwen P J, Stricker P, Hruby G, et al. (68) GaPSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment[J].BJU Int, 2016, 117 (5):732-739.
[28]	Kim M Y, Oskarsson T, Acharyya S, et al.Tumor selfseeding by circulating cancer cells[J].Cell, 2009, 139 (7):1315-1326.
[29]	Zabell J R, Adejoro O, Jarosek S L, et al.Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer:apopulation-based, propensity-weighted multivariable analysis[J].World JUrol, 2016, 34 (10):1397-1403.